Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

Which peptides are studied in relation to glycogen storage?

A research-supply review of the peptides and peptide-adjacent compounds examined in laboratory and clinical studies for their relationship to glycogen storage, including hCG, IGF-I, irisin, and the glucokinase activator

peptides-pro Editorial

The peptide most directly named in the glycogen-storage literature is insulin-like growth factor I (IGF-I), also written IGF-1, a 70-amino-acid single-chain polypeptide of approximately 7.6 kDa that belongs to the insulin/IGF superfamily and signals through the IGF-I receptor (IGF1R), a receptor tyrosine kinase. In doping-control technical work, IGF-I is described among the most-used hormones in sport and appears on the WADA list of banned molecules, where its stated actions include stimulating muscle protein synthesis, promoting glycogen storage, and improving lipolysis [1]. Human chorionic gonadotropin (hCG), a heterodimeric glycoprotein hormone, is named alongside IGF-I in the same analytical context, though the glycogen-storage language in that source attaches to IGF-I rather than to hCG [1].

The pathway that organises most of this work is insulin/IGF-I receptor signalling and its downstream control of glucose uptake and storage, with hepatic glucose metabolism and skeletal-muscle glucose handling as the two tissue-level nodes that recur across the studies below.

Research Studies

IGF-I and glycogen storage in athletes (analytical context)

The clearest statement in the supplied evidence linking a peptide to glycogen storage comes from a method-development paper on dried blood spot analysis. That technical note reports that male athletes may use pharmaceutical IGF-I preparations to stimulate muscle protein synthesis, promote glycogen storage, and improve lipolysis, and it frames hCG and IGF-I as two of the most-used hormones in sport and both WADA-banned [1]. The paper's own contribution is analytical: a UHPLC-MS/MS method for measuring hCG and IGF-I from dried blood spots, a microsampling strategy proposed to improve compound stability, simplify sample collection and pre-analytical phases, and facilitate automation in doping control [1]. No dose-response, no tissue-level mechanism, and no outcome data on glycogen content are provided; the glycogen-storage claim is reported as a rationale for why the analytes matter, not as a finding of the study.

Dorzagliatin and hepatic glycogen storage in pancreatic-insufficient cystic fibrosis

Dorzagliatin is a small-molecule glucokinase activator rather than a peptide, and it is included here because the registered protocol names hepatic glycogen storage as an endpoint. A clinical trial in individuals with pancreatic-insufficient cystic fibrosis and abnormal glucose tolerance is designed to determine the pharmacokinetic and pharmacodynamic response to dorzagliatin 50 mg twice daily after 7-day administration, compared with randomized, double-blind 7-day placebo in a crossover fashion [2]. The stated hypothesis is that dorzagliatin administration will produce significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage, the latter assessed during a standardized mixed-meal tolerance test [2]. This is a protocol hypothesis in a defined patient population; the evidence block contains no results.

Exercise fuel selection and the muscle glycogen rationale

A separate registered study on maximal fat oxidation and fuel use during exercise sets out the physiological framing that connects exercise intensity and feeding status to fuel selection. It notes that fat and carbohydrate are the two main energy stores available during exercise, that fat is the primary fuel during prolonged low-to-moderate-intensity exercise, and that strategies to maximize muscle glycogen storage and elevate fat oxidation have been studied with the aim of preserving limited muscle glycogen stores and improving endurance performance [3]. The same source defines maximal fat oxidation as the highest rate of fat oxidation across all exercise intensities [3]. This is background physiology rather than a peptide finding, and it does not test any peptide.

Irisin and hepatic glucose metabolism in insulin-deficient mice

Irisin, an exercise-induced hormone, has been examined for direct regulation of hepatic glucose metabolism under insulin-deficient conditions. Work in Akita mice reports that irisin gene delivery produced sustained amelioration of diabetes through insulin-independent regulation of hepatic glucose metabolism, addressing whether irisin can act directly on the liver when insulin signalling is deficient [4]. The model is a mouse model of insulin deficiency; the findings are animal-only and should not be read as established in humans.

Skeletal muscle biomass as a fate of glucose

A review of glucose handling in skeletal muscle argues that glucose is traditionally viewed as a substrate for ATP production and glycogen storage, and assembles evidence that glucose also serves as a building block for biomass synthesis in proliferating muscle satellite (stem) cells and in hypertrophying skeletal muscle fibres, drawing parallels to anabolic processes in other systems [5]. This reframes glycogen storage as one of several competing fates for glucose in muscle rather than the terminal one. It is a review, not primary experimental work, and it does not evaluate a peptide.

Where the evidence sits by model and compound

CompoundClassModel or populationGlycogen-related content in the evidence
IGF-IPeptide hormone (approx. 7.6 kDa)Male athletes (reported use context)Named as promoting glycogen storage; analytical method only [1]
hCGGlycoprotein hormoneMale athletes (reported use context)Named as banned and analysed; no glycogen claim [1]
DorzagliatinSmall-molecule glucokinase activatorPancreatic-insufficient cystic fibrosis with abnormal glucose toleranceHepatic glycogen storage as a protocol hypothesis [2]
IrisinExercise-induced hormoneAkita mice (insulin-deficient)Hepatic glucose metabolism; animal-only [4]

What the evidence does not establish

Across the supplied sources, no study reports a measured change in glycogen content in humans following peptide administration. The IGF-I glycogen-storage statement is a rationale in a doping-control methods paper [1]; the dorzagliatin glycogen endpoint is a hypothesis in a registered protocol [2]; the exercise source supplies physiological background without testing a compound [3]; the irisin work is in mice [4]; and the muscle-biomass review is conceptual [5]. Any statement that a given peptide increases glycogen storage in humans is not supported by this evidence block.

Analytical considerations for laboratory work

For laboratories handling these analytes, the supplied method paper is relevant to pre-analytical practice: dried blood spot microsampling was developed for hCG and IGF-I with the stated aims of improving compound stability, simplifying sample collection and pre-analytical phases, and facilitating automation [1]. Researchers designing assays around peptide hormones should note that stability and matrix effects are treated as method-development problems in that source rather than as settled parameters.

If you are reading this for personal health reasons

The materials described here are supplied for laboratory research use only, and nothing on this page is medical advice. We do not provide dosing information or guidance on using any compound in a person. If you are considering a compound for yourself, speak to a licensed clinician.

Sources

WhatsApp